Merck & Company Inc (MRK)vsVeru Inc (VERU)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
VERU
Veru Inc
$3.40
-19.62%
HEALTHCARE · Cap: $48.55M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 389373% more annual revenue ($65.77B vs $16.89M). MRK leads profitability with a 13.6% profit margin vs 0.0%. VERU appears more attractively valued with a PEG of 3.60. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
VERU
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+20.0%
Fair Value
$2.80
Current Price
$3.40
$0.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
18.3% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : VERU
The strongest argument for VERU centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 18.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : VERU
The primary concerns for VERU are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while VERU is a growth play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.20 — expect wider price swings.
VERU is growing revenue faster at 18.3% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 38/100). VERU offers better value entry with a 20.0% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Veru Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. The company is headquartered in Miami, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?